If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning Laura, Interesting posts of late and thanks. Lets see if conference attendance results in contracts. Lucky to get your £700.00 order yesterday by the look of things there's no stock available today, well at present anyway!
FY June 2024-25 looks good with £0.6mln already booked in before it even starts and also due to hear from
Biostatistics service line
The Company was excited to announce its intention to develop a separate consulting service line focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution to the Company's revenues and bottom line in the financial year ending 30 June 2025.
BioPartner UK is the independent, accredited trade organisation that supports UK international trade
We work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for our members and UK companies travelling with outward delegations. BioPartner also provides access to entry fee discounts for key Life Science conferences.
The BIO International Convention is the largest biotechnology event of the year, with >20,000 industry leaders attending from across the globe. Physiomics’ CEO, Peter Sargent, and Head of Business Development, Hayley Close will be attending the event to meet with decision makers from leading pharma & biotech companies. Physiomics will be looking to identify opportunities where the company’s expertise in quantitative pharmacology and PKPD modelling can be applied to derisk R&D of therapeutics drugs, across indications for the companies attending.
Pyc attending this (Hopefully getting 15% discount of the $3550 fee now they’re member).
https://www.physiomics.co.uk/bio-2024/
Welcome to the @BioPartner family, @Physiomics.
We are looking forward to a wonderful #partnership with exciting #opportunities ahead. 🤝
Hard buying again , I managed £700
Https://www.biopartner.co.uk/
https://www.biopartner.co.uk/membership as they are a company, they pay £500 per year
Great news
Physiomics now a member. ( Think they had to pay for this)
https://x.com/physiomics/status/1787824338835542193?s=61&t=0G9XeE3tHfuoBf1VEsPycQ
Some nice buys today. Hopefully we will hear news soon of further contracts
Cancer experts have claimed that the UK is entering a 'cancer renaissance' with personalised jabs to combat some of the deadliest tumours expected by 2030.
The vaccines are designed to target specific genetic mutations found in cancer cells. This means that, should the cancer return, the immune system will spot it immediately and destroy the cells before they have time to spread.
Kate Bingham tells NHS to launch experimental cancer vaccine trials with pioneering technology that trains the immune system how to hunt malignant cells
https://www.dailymail.co.uk/health/article-13383755/Former-Covid-jab-tsar-tells-NHS-launch-experimental-cancer-vaccine-trials-pioneering-technology-trains-immune-hunt-malignant-cells.html
“Dr Lennard Lee, a cancer vaccine expert at the University of Oxford, said there are now 12 drug manufacturers testing cancer jabs in the UK. He added: 'We are already gaining the reputation as the best country in the world to develop cancer vaccines.'
This was a post on linked in from a month ago
Robert Watson
•
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
1mo •
From a month ago F
Fascinating to attend an investigator meeting for Scancell Ltd's SCOPE study - the second meeting for a
hashtag
#cancervaccine clinical trial in melanoma that I've been to in the space of a few weeks. Great to hear about the immunology underpinning the therapy and enjoyable to interact with other trial teams around the UK. It is really fantastic to be able to offer these cutting-edge clinical trials to our patients at Oxford University Hospitals NHS Foundation Trust and see such rapid ongoing progress in the cancer vaccine space
Only a small shareholder but how I see it. Pete Sargent has only been in charge a few months, we really need to give him 12 months to stamp his authority and guide Physiomics in his own style. He has a proven track record and I think the majority are still positive of the direction Physiomics can take over next 12-24 months. If we arent over £1 million in sales pro rata per year by December 24 then yes questions will be asked. If possible a few directors buys wouldnt go amiss to settle the share price and get the positivity going again.
That was a master service agreement where they pledge to spend c£500knler annum ..been in place last 4yrs+ (see JM presentation 2023)
I
Thank you Ant / Laura.
Was there not a £500k contract with Merck some years ago?
To my knowledge the largest single contract publicly named was £125k in mid 2023
So one or both of these are £175+ which suggests clients are ready to spend more and more with the proven tech and mgmt
Approximately £350k. Whilst the Board anticipates that the contracts for these two projects will be signed in FY24
Yesterday confirmed
1) largest ever start to a FY (2025)
2) 2 large contracts (one/both some of largest ever hence totalling £325k and another new client
3 revenue will singly be recognised outside of the FY24 trading time period
Obviously annoying but the price action bounce back was hopefully a recognition of all of the above
Debull etc
It doesn't really matter what others say in my view, one absorbs all POVs but ultimately we make our own choices based on the information
DB I wouldn't take any notice, I don't . I have continued to add as price fluctuations present further opportunities for buying and will continue to do so. Have a good w/e we'll further I have no doubt. Ant
Ant, how would you reply to the posters that gave their POV yesterday & have a very negative view on PYC? Or would a reply just give them oxygen, so no point fanning the flames?
TIA.
Yes I am still buying and have done so both yesterday and today. I am not surprised that the transition as a mindset from wet lab to computer takes as long as it does and quite naturally delays contracts . It has taken 20 years for the FDA to agree the technology and subsequently embrace it. The model is in place and well positioned to be advanced. PYC has a future in an ever expanding sector within the pharmaceutical industry. I have waited patiently for this point in time and will as ever await the rewards it will undoubtedly afford. I am pleased to note the enthusiasm of management of late long may it last. As ever time will tell, take no notice of those that are hell bent on profiteering at this stage and hold for what is an emerging story...not before time but through no fault of their own. The FDA reigns supreme The clock will not be turned back nor the need to produce drugs and dosing regimes economically. Time lines to drug both expensive and time consuming need to be reduced, modelling and computer technology when accurate, present both these possibilities !
Clearly disappointing news in the short term, but more encouraging longer term if the delayed contracts are signed off as expected
Surprisingly low volume traded - looks like most, like me, are staying put